Based on the active functional groups of B7, compound target prediction combined with Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses revealed that B7 may exert anti‐GBM effects by modulating key immune regulatory processes, including leukocyte activation, lymphocyte activation, leukocyte migration, and immune response activation (Figure S5A, Supporting Information). The gene discussed is CD80; the disease is glioblastoma.